Tags

Type your tag names separated by a space and hit enter

Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
Curr Med Res Opin. 2007 Sep; 23(9):2125-33.CM

Abstract

OBJECTIVE

To compare effectiveness of rosuvastatin (RSV) with other statins on lowering low-density lipoprotein cholesterol (LDL-C) and LDL-C goal attainment among patients with type 1 or type 2 diabetes mellitus.

METHODS

A retrospective study using US General Electric Medical Systems (GEMS) database of patients with diabetes mellitus (ICD9 code = 250, prescription for anti-diabetic medication or fasting blood glucose level > or = 126 mg/dL in the 12 months preceding statin therapy) treated across clinical practices in the US, who were newly prescribed statin therapy during August 2003-March 2006, was conducted. Multivariate linear and logistic regression models were used for analyzing prescription data with baseline LDL-C, age, gender, smoking, very high CHD risk, systolic blood pressure, and statin duration as covariates.

RESULTS

Of 4754 diabetes mellitus patients, 5% were prescribed RSV, 59% atorvastatin (ATV), 21% simvastatin (SMV), 5% pravastatin (PRV), 2% fluvastatin (FLV), and 7% lovastatin (LOV). RSV patients had significantly higher (p < 0.05) baseline mean LDL-C levels (138 vs. 117-131 mg/dL), lower average starting dose (11.7 vs. 17.0-63.7 mg) and were younger (p < 0.005) than patients on other statins (mean age 61 vs. 63-69 years). Percent LDL-C reduction was significantly greater (p < 0.0001) with RSV (28.4%) compared to ATV (22.5%), SMV (20.1%), PRV (13.7%), FLV (15.8%), and LOV (17.3%). A greater (p < 0.05) proportion of RSV diabetes patients attained LDL-C goal < 100 mg/dL (72.8%) vs. diabetes mellitus patients on other statins (36.8-67.4%).

CONCLUSIONS

Rosuvastatin was more effective in lowering LDL-C and achieving LDL-C treatment goals in the diabetes mellitus population as compared to other statins in real-world clinical practice setting. Validating study results in a different diabetes population with dispensed statin prescriptions will help increase generalizability of study findings.

Authors+Show Affiliations

University of Maryland School of Medicine, Department of Epidemiology & Preventive Medicine, Baltimore, MD, USA. kathyfox@comcast.netNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Practice Guideline
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17655813

Citation

Fox, Kathleen M., et al. "Effectiveness of Rosuvastatin in Low-density Lipoprotein Cholesterol Lowering and National Cholesterol Education Program Adult Treatment Panel Guideline III LDL-C Goal Attainment Compared to Other Statins Among Diabetes Mellitus Patients: a Retrospective Study Using an Electronic Medical Records Dataset in the United States." Current Medical Research and Opinion, vol. 23, no. 9, 2007, pp. 2125-33.
Fox KM, Gandhi SK, Ohsfeldt RL, et al. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States. Curr Med Res Opin. 2007;23(9):2125-33.
Fox, K. M., Gandhi, S. K., Ohsfeldt, R. L., Blasetto, J. W., & Bays, H. E. (2007). Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States. Current Medical Research and Opinion, 23(9), 2125-33.
Fox KM, et al. Effectiveness of Rosuvastatin in Low-density Lipoprotein Cholesterol Lowering and National Cholesterol Education Program Adult Treatment Panel Guideline III LDL-C Goal Attainment Compared to Other Statins Among Diabetes Mellitus Patients: a Retrospective Study Using an Electronic Medical Records Dataset in the United States. Curr Med Res Opin. 2007;23(9):2125-33. PubMed PMID: 17655813.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States. AU - Fox,Kathleen M, AU - Gandhi,Sanjay K, AU - Ohsfeldt,Robert L, AU - Blasetto,James W, AU - Bays,Harold E, PY - 2007/7/28/pubmed PY - 2007/11/14/medline PY - 2007/7/28/entrez SP - 2125 EP - 33 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 23 IS - 9 N2 - OBJECTIVE: To compare effectiveness of rosuvastatin (RSV) with other statins on lowering low-density lipoprotein cholesterol (LDL-C) and LDL-C goal attainment among patients with type 1 or type 2 diabetes mellitus. METHODS: A retrospective study using US General Electric Medical Systems (GEMS) database of patients with diabetes mellitus (ICD9 code = 250, prescription for anti-diabetic medication or fasting blood glucose level > or = 126 mg/dL in the 12 months preceding statin therapy) treated across clinical practices in the US, who were newly prescribed statin therapy during August 2003-March 2006, was conducted. Multivariate linear and logistic regression models were used for analyzing prescription data with baseline LDL-C, age, gender, smoking, very high CHD risk, systolic blood pressure, and statin duration as covariates. RESULTS: Of 4754 diabetes mellitus patients, 5% were prescribed RSV, 59% atorvastatin (ATV), 21% simvastatin (SMV), 5% pravastatin (PRV), 2% fluvastatin (FLV), and 7% lovastatin (LOV). RSV patients had significantly higher (p < 0.05) baseline mean LDL-C levels (138 vs. 117-131 mg/dL), lower average starting dose (11.7 vs. 17.0-63.7 mg) and were younger (p < 0.005) than patients on other statins (mean age 61 vs. 63-69 years). Percent LDL-C reduction was significantly greater (p < 0.0001) with RSV (28.4%) compared to ATV (22.5%), SMV (20.1%), PRV (13.7%), FLV (15.8%), and LOV (17.3%). A greater (p < 0.05) proportion of RSV diabetes patients attained LDL-C goal < 100 mg/dL (72.8%) vs. diabetes mellitus patients on other statins (36.8-67.4%). CONCLUSIONS: Rosuvastatin was more effective in lowering LDL-C and achieving LDL-C treatment goals in the diabetes mellitus population as compared to other statins in real-world clinical practice setting. Validating study results in a different diabetes population with dispensed statin prescriptions will help increase generalizability of study findings. SN - 1473-4877 UR - https://www.unboundmedicine.com/medline/citation/17655813/Effectiveness_of_rosuvastatin_in_low_density_lipoprotein_cholesterol_lowering_and_National_Cholesterol_Education_Program_Adult_Treatment_Panel_guideline_III_LDL_C_goal_attainment_compared_to_other_statins_among_diabetes_mellitus_patients:_a_retrospective_study_using_an_electronic_medical_records_dataset_in_the_United_States_ L2 - https://www.tandfonline.com/doi/full/10.1185/030079907X219580 DB - PRIME DP - Unbound Medicine ER -